Perrigo Company plc and Galapagos NV: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Perrigo Company plc and Galapagos NV have showcased contrasting approaches. Perrigo, a leader in over-the-counter health products, consistently allocated a significant portion of its budget to SG&A, peaking at approximately 1.27 billion in 2023. This represents a steady increase of around 89% from 2014. In contrast, Galapagos NV, a biotech innovator, demonstrated a more volatile pattern, with a notable surge in 2022, reaching nearly 240 million, a staggering 2,500% increase from 2014. These trends highlight Perrigo's stable growth strategy versus Galapagos's dynamic investment in innovation. As the industry evolves, understanding these spending patterns offers valuable insights into each company's strategic priorities and market positioning.